Actavis Malta

  • We are the New Actavis. A Global Leader in Generics. NYSE : ACT.We are the New Actavis. A Global Leader in Generics. NYSE : ACT.

    ACT: An Emerging Leader in Specialty Pharmaceuticals

  • We are the New Actavis. A Global Leader in Generics. NYSE : ACT.We are the New Actavis. A Global Leader in Generics. NYSE : ACT.

    A Generics Leader in 60+ Global Markets

  • We are the New Actavis. A Global Leader in Generics. NYSE : ACT.We are the New Actavis. A Global Leader in Generics. NYSE : ACT.

    A Specialty Brands Leader in Women’s Health

  • We are the New Actavis. A Global Leader in Generics. NYSE : ACT.We are the New Actavis. A Global Leader in Generics. NYSE : ACT.

    Expanding Specialty Brands into Key Global Markets

  • We are the New Actavis. A Global Leader in Generics. NYSE : ACT.We are the New Actavis. A Global Leader in Generics. NYSE : ACT.

    Accelerating a Foundation in Biosimilars

Actavis + Allergan

On March 17th, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The combined company has broad commercial reach extending across approximately 100 countries and is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team.

The Actavis + Allergan Brand portfolio features six blockbuster franchises in key therapeutic categories, including Dermatology and Aesthetics; CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular and Infectious Disease. Supporting these blockbuster franchises is the company’s industry-leading specialty and primary care U.S. sales force with extraordinary marketing reach and increased relevance with primary care physicians and specialists.

The Actavis + Allergan Generics portfolio features more than 1,000 generics, branded generics, established brands and OTC products. The combined company is the third largest generic manufacturer in the U.S. and holds a top 5 leadership position in nearly 20 International markets.
Driving continued innovation and growth is the combined company’s strong commitment to R&D, with an investment of ~$1.7 billion in 2015 alone, focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.
Learn more about this exciting combination at www.Actavis.com

Actavis Malta, has highly trained and dedicated employees, a favourable patent environment and state-of-the-art manufacturing facilities, making Malta a key contributor to the Actavis group of companies.

News

News Archive

Featured Products

Histasin Tablets

Hay fever (allergic rhinitis), is an allergic reaction caused by proteins of pollen, dust and mould. These particles lodge in the nasal lining and parts of the respiratory tract where they initiate an allergic response. Symptoms include nasal congestion, runny nose, sneezing, itchy nose and eyes, excessive tear production and an irritating dry cough.

More information

Actavis Malta